Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans
- PMID: 8277100
- DOI: 10.1016/0735-1097(94)90505-3
Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans
Abstract
Objectives: The purpose of this study was to assess the effect of different degrees of ischemia on circulating and cardiac neurohormones and vasotone.
Background: Neuroendocrine activation and subsequent systemic vasoconstriction may complicate ischemia. Whether this relates to severity of ischemia and subsequent cardiac dysfunction, and whether neurohormonal balance in the ischemic area changes, is unknown.
Methods: Fifty-six normotensive patients with coronary artery disease were evaluated during incremental atrial pacing. On the basis of ST segment changes, patients were classified in a nonischemic (n = 11) or ischemic group (n = 45), the latter patients were subsequently classified as lactate (n = 28) or nonlactate (n = 17) producing, to identify neurohormonal changes in the effluent of the ischemic myocardium.
Results: Angina occurred in 55%, 82% and 82% of patients in the nonischemic, lactate- and nonlactate-producing groups, respectively. Baseline hemodynamic variables and neurohormones were comparable in all groups, as were heart rate, rate-pressure product and coronary hemodynamic variables during pacing. In lactate producers, contractility did not improve, relaxation deteriorated, left ventricular filling pressure increased and cardiac output decreased during pacing, indicating more severe ischemia compared with that in nonlactate producers. Neurohormones did not change in the nonischemic group. In contrast, arterial and coronary venous catecholamines increased significantly more in lactate producers than in nonlactate producers (arterial norepinephrine by 68% vs. 36%, respectively). Moreover, arterial angiotensin II increased in lactate producers from a baseline mean +/- SEM of 6.8 +/- 0.9 to 9.7 +/- 1.6 pmol/liter (p < 0.05), accompanied by a sustained 23% increase in systemic resistance and arterial pressures. In lactate producers, baseline net cardiac norepinephrine release changed to net uptake during pacing (-0.05 +/- 0.02 vs. 0.06 +/- 0.05 nmol/min, p < 0.05). Epinephrine uptake increased in all patients with ischemia, albeit more in lactate producers.
Conclusions: Circulating catecholamines and renin-angiotensin levels are activated, and systemic vasotone is increased in relation to the degree of ischemia. Cardiac epinephrine uptake increases, whereas net baseline norepinephrine release from the ischemic myocardium changes to net uptake. Modulation of this neurohormonal activation may provide an alternative mode to limit ischemia.
Similar articles
-
Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris.Am J Cardiol. 1991 Jul 15;68(2):181-6. doi: 10.1016/0002-9149(91)90741-3. Am J Cardiol. 1991. PMID: 2063779
-
Acute myocardial ischaemia induces cardiac carnitine release in man.Eur Heart J. 1997 Jan;18(1):84-90. doi: 10.1093/oxfordjournals.eurheartj.a015122. Eur Heart J. 1997. PMID: 9049519
-
Hemodynamic tolerability and anti-ischemic efficacy of high dose intravenous diltiazem in patients with normal versus impaired ventricular function.J Am Coll Cardiol. 1993 Mar 1;21(3):709-20. doi: 10.1016/0735-1097(93)90104-9. J Am Coll Cardiol. 1993. PMID: 8436753
-
Effect of ACE inhibition on neurohormones.Eur Heart J. 1998 Sep;19 Suppl J:J16-23. Eur Heart J. 1998. PMID: 9796836 Review.
-
Catecholamines in myocardial ischemia. Systemic and cardiac release.Circulation. 1990 Sep;82(3 Suppl):II13-22. Circulation. 1990. PMID: 2203558 Review.
Cited by
-
Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: Role of adrenergic overdrive and lipolysis byproducts.Sci Rep. 2019 Aug 14;9(1):11841. doi: 10.1038/s41598-019-48356-1. Sci Rep. 2019. PMID: 31413360 Free PMC article.
-
Predictors in no-reflow phenomenon in acute myocardial infarction with ST-segment elevation.Arch Cardiol Mex. 2022;92(4):461-468. doi: 10.24875/ACM.21000346. Arch Cardiol Mex. 2022. PMID: 36413699 Free PMC article. English.
-
Coronary vessel diameters during and after primary percutaneous coronary artery intervention.Herz. 2014 Jun;39(4):515-21. doi: 10.1007/s00059-013-3865-4. Epub 2013 Jul 7. Herz. 2014. PMID: 23831831 Clinical Trial.
-
Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?Drugs. 1997;54 Suppl 5:59-70. doi: 10.2165/00003495-199700545-00009. Drugs. 1997. PMID: 9429846 Review.
-
No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case-control study (NORM PPCI).Open Heart. 2020 Jul;7(2):e001215. doi: 10.1136/openhrt-2019-001215. Open Heart. 2020. PMID: 32719072 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources